US Broker Ratings

Alnylam Pharmaceuticals, Inc. (ALNY): Investor Outlook Reveals 10.57% Potential Upside and Robust Pipeline

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), a leader in the biotechnology sector, continues to intrigue investors with its promising pipeline and strategic collaborations. Headquartered in Cambridge, Massachusetts, Alnylam specializes in the..

Halozyme Therapeutics, Inc. (HALO) Stock Analysis: A Biotech Powerhouse with 22.85% Potential Upside

Halozyme Therapeutics, Inc. (NASDAQ: HALO) is carving a niche in the biotechnology sector with its innovative enzyme-based drug delivery solutions. With a market capitalization of $6.72 billion, this San Diego-based..

Merit Medical Systems, Inc. (MMSI) Stock Analysis: Growth Potential with a 13.80% Upside

Merit Medical Systems, Inc. (NASDAQ: MMSI), a prominent player in the healthcare sector, has been capturing investor attention with its innovative medical instruments and supplies. Based in South Jordan, Utah,..

Jazz Pharmaceuticals (JAZZ) Stock Analysis: Exploring a 70.97% Potential Upside

Investors on the lookout for opportunities in the biotechnology sector should consider Jazz Pharmaceuticals plc (NASDAQ: JAZZ), a company headquartered in Dublin, Ireland. Specializing in developing and commercializing pharmaceutical products,..

BioNTech SE (BNTX) Stock Analysis: A 34.66% Potential Upside Amidst Biotech Challenges

BioNTech SE (BNTX), a prominent player in the biotechnology sector, has been a focal point for investors with its promising pipeline of immunotherapies aimed at combating cancer and infectious diseases...

HCA Healthcare, Inc. (HCA) Stock Analysis: Robust Revenues and Analyst Confidence Highlight Investment Potential

HCA Healthcare, Inc. (NYSE: HCA) stands as a formidable entity in the healthcare sector, particularly within the medical care facilities industry. With a robust market capitalization of $90.6 billion, HCA..

BrightSpring Health Services, I (BTSG)

⚠️ No article content returned.

..

Repligen Corporation (RGEN) Stock Analysis: Navigating a Potential 54.99% Upside with Strong Buy Ratings

For investors keen on the healthcare sector, Repligen Corporation (NASDAQ: RGEN) presents a compelling case for consideration, particularly with its attractive potential upside of nearly 55%. As a leading player..

Centene Corporation (CNC) Stock Analysis: A Healthcare Leader with 38.44% Potential Upside

Investors eyeing the healthcare sector should pay close attention to Centene Corporation (NYSE: CNC), a prominent player in the healthcare plans industry. With a market capitalization of $28.07 billion, Centene..

Natera, Inc. (NTRA) Stock Analysis: Unpacking a 25% Upside Potential in the Diagnostics Arena

Natera, Inc. (NASDAQ: NTRA) stands prominently in the healthcare sector, specifically within the diagnostics and research industry. Headquartered in Austin, Texas, this innovative company has carved a niche for itself..

Legend Biotech Corporation (LEGN): Investor Outlook Highlights 165% Potential Upside Amidst Strong Buy Ratings

Legend Biotech Corporation (NASDAQ: LEGN) is capturing the attention of investors with its promising potential upside of 165.40%, driven by an impressive array of buy ratings and a robust pipeline..

Ascendis Pharma A/S (ASND) Stock Analysis: Unpacking a 38.64% Potential Upside

Ascendis Pharma A/S (NASDAQ: ASND), a Danish biopharmaceutical company, has made headlines in the healthcare sector with its promising therapeutic developments and strategic market positioning. As a key player in..

Glaukos Corporation (GKOS) Stock Analysis: A 27% Upside Potential in the Medical Devices Sector

Glaukos Corporation (NYSE: GKOS), a leading player in the healthcare sector, specifically within the medical devices industry, offers a compelling proposition for investors seeking growth in the ophthalmic medical technology..

Prestige Consumer Healthcare Inc. (PBH) Stock Analysis: Navigating a 3.21% Upside Potential

Prestige Consumer Healthcare Inc. (NYSE: PBH) stands as a formidable player in the healthcare sector, specifically within the niche of over-the-counter (OTC) drug manufacturing. With a market capitalization of $4.24..

Axsome Therapeutics (AXSM) Stock Analysis: A Biotech Gem with 68% Upside Potential

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a prominent player in the biotechnology sector, has captured investor interest due to its innovative focus on central nervous system (CNS) disorders and a compelling..

Abbott Laboratories (ABT) Stock Analysis: Exploring a 7% Potential Upside in the Healthcare Giant

Abbott Laboratories (NYSE: ABT), a titan in the healthcare industry, continues to capture the attention of investors with its robust operations and promising market position. With a market capitalization of..

Corcept Therapeutics (CORT) Stock Analysis: A Look at Its 75.69% Potential Upside and Promising Pipeline

Corcept Therapeutics Incorporated (CORT), a prominent player in the biotechnology sector, is captivating investor attention with its ambitious clinical pipeline and impressive potential upside. With a market capitalization of $8.34..

Mettler-Toledo International, Inc. (MTD) Stock Analysis: Navigating a Competitive Diagnostics Landscape with 11.78% Upside Potential

Mettler-Toledo International, Inc. (NYSE: MTD) is a key player in the Healthcare sector, particularly within the Diagnostics & Research industry. Headquartered in Columbus, Ohio, the company has etched its name..

Regencell Bioscience Holdings L (RGC) Stock Analysis: Navigating the 52-Week High and Future Prospects

Regencell Bioscience Holdings Limited (NASDAQ: RGC) has recently captured the attention of investors as it reached a staggering 52-week high of $560.00. This Hong Kong-based company operates within the healthcare..

RadNet, Inc. (RDNT) Investor Outlook: Analyzing a 27.19% Upside Potential

In the ever-evolving landscape of healthcare diagnostics, RadNet, Inc. (NASDAQ: RDNT) stands out as a formidable player. With a market capitalization of $4.25 billion, this Los Angeles-based company has carved..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds